Norfolk, VA, May 28, 2020 — ReAlta Life Sciences, Inc. announced today that it will participate in the upcoming virtual BIO International Convention, BIO Digital, being held June 8 – 12, 2020. The ReAlta team will meet virtually with biotechnology companies as well as institutional investors to discuss its dual targeting peptide technology platform and co-development opportunities in the areas of hypoxic-ischemic encephalopathy (HIE) and acute lung injury.
About BIO — BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
ABOUT REALTA — ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. To support its vision, ReAlta has developed a novel class of therapeutics with a dual targeting approach designed to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071 (PIC1-dPEG24), which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia.
Companies interested in meeting with ReAlta at BIO Digital are asked to contact Michael Simet at email@example.com.